Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.
Cizzle Biotechnology Holdings PLC has partnered with Moffitt Cancer Center to utilize its CIZ1B biomarker assay in a clinical evaluation targeting the early detection of lung cancer. This collaboration marks the first instance where patients with suspicious lung nodules will be tested using Cizzle’s biomarker blood test, potentially improving accuracy in early-stage cancer diagnosis and reducing false positives from CT scans. The initiative is part of a broader strategy to establish the CIZ1B test across North America and demonstrates a significant step towards commercialization and global market entry.
For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.
